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Type 2 diabetes (T2D) is associated with dysbiosis of the gut microbiota, though diabetes treatment regi-
mens, including metformin, may confound the results. Forslund et al. (2015) identify distinct disease and
drug signatures and highlight the importance of adjusting for treatment when investigating how T2D influ-
ences the human gut microbiome.Type 2 diabetes (T2D) is a chronic disor-
der characterized by elevated blood
glucose levels due to a combination of in-
sulin resistance and insufficient insulin
secretion, and its prevalence is increasing
at an alarming rate worldwide. This com-
plex disease results from interactions be-
tween genetic and environmental factors,
and several risk factors including age,
family history, dietary habits, sedentary
lifestyle, and obesity have been identified.
Recent studies analyzing the gut metage-
nome have also indicated that dysbiosis
of the human gut microbiota is associated
with T2D (Karlsson et al., 2013; Qin et al.,
2012). Considering that the human body
contains ten times more bacteria than hu-
man cells, it is essential to determine the
specific contribution of the human gut mi-
crobiome to T2D pathogenesis to allow
for the development of effective treatment
strategies. However, most of the earlier
gut metagenomic studies linking gut mi-
crobiota composition and chronic dis-
ease have not accounted for the effectsof treatment regimens on the composition
of the gut microbiome. An elegant study
by Forslund et al. (2015) published in
Nature now tackles this issue and iden-
tifies specific disease and drug signatures
in the human gut microbiome of T2D pa-
tients (Figure 1A).
Forslund et al. (2015) performed a
meta-analysis of metagenomic data from
199 T2D patients, from whom informa-
tion on antidiabetic treatment was avail-
able, and 554 non-diabetic controls,
comprising Swedish, Danish, and Chi-
nese individuals. By analyzing the dataset
without stratifying for treatment regimens,
they replicated the majority of previously
reported results and showed a large
divergence between the study popula-
tions. They then tested for the effect of
diet and treatment regimens and found a
significant effect only for metformin,
currently one of the most widely used
antidiabetic drugs. After stratifying the
T2D patients according to whether or
not they were treated withmetformin, For-slund et al. (2015) found differences in gut
taxonomic composition between metfor-
min-untreated T2D patients and non-
diabetic controls. Using a supervised
learning method for classification, regres-
sion, and outlier detection, the authors
were able to identify which T2D patients
were treated with metformin based on
their gut microbial composition. As re-
ported in previous studies (Karlsson
et al., 2013; Qin et al., 2012), the abun-
dance of bacterial genera containing
known butyrate producers was lower in
metformin-untreated T2D patients than
in non-diabetic controls. Conversely, the
increase in Lactobacillus seen previously
in T2D patients without accounting for
treatment regimen was eliminated when
controlling for metformin treatment.
Biological pathway analysis based on
microbial gene functions showed that
metformin-untreated T2D patients were
enriched in genes involved in responses
to oxidative stress, such as catalase, as
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Figure 1. Stratification of the T2D Patients Based on Their Treatment Regimen
(A) Forslund et al. (2015) demonstrate that one of the most widely used antidiabetic drugs, metformin, confounds the results of the metagenomics data analysis.
The authors provide evidence for the microbial-mediated effect of metformin treatment by disentangling the effects of T2D from those of metformin.
(B) Microbial genes responsible for the degradation of glycine, tryptophan, arginine, and threonine differ between metformin-untreated T2D patients and non-
diabetic control subjects. The gut microbiota alters the metabolism of amino acids along the gastrointestinal tract, and thus the gut microbiota may directly affect
T2D through its effect on amino acids.
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lating threonine and arginine degradation
and pyruvate synthase capacity. Further-
more, alterations in these microbial gene
modules correlated with abundance of
altered bacterial taxa in these patients.
To separate dysglycemia effects from
T2D-specific microbial features, Forslund
et al. (2015) also compared metagenomic
data from 31 T1D patients with data from
non-diabetic controls and showed that
the majority of gut microbiota changes in
metformin-untreated T2D are directly or
indirectly associated with the onset or
progression of T2D rather than merely an
effect of dysglycemia.
To investigatewhethermetforminmedi-
ates its therapeutic effect partly through
modulation of the microbiota, the authors
compared metagenomics data from
metformin-treated T2D patients to T2D
patients treated with other antidiabetic
medications (e.g., sulfonylurea, dipeptidyl
peptidase-4 [DPP4] inhibitors, or
glucagon-like peptide-1 [GLP1]). The dif-
ferences were small, with multivariate
analysis showing significant differences
only at the bacterial family level between
metformin-treatedand -untreatedT2Dpa-
tients. However, univariate tests for spe-
cific taxa showed stronger signals than
seen between metformin-untreated T2D
patients and controls. Metformin-treatedT2Dpatients fromall threepopulations ex-
hibited a decrease in the abundance of
Intestinibacter spp., whereas a significant
increase in the abundance of Escherichia
spp. was found in metformin-treated T2D
patients only from theDanishandSwedish
populations. Functional analyses showed
that gut microbiota of metformin-treated
T2D patients had increased potential for
butyrate and propionate production,
whichmay in turn contribute to the benefi-
cial effect of metformin.
Identification of taxonomic and func-
tional microbiome signatures of metfor-
min-untreated T2D patients will improve
our understanding of the key roles played
by the gut microbiome in the occurrence
of T2D. Indeed, butyrate producing bac-
teria, which were lower in T2D patients
after controlling for metformin treatment,
have been shown to have health benefits
(Wong et al., 2006). Moreover, Forslund
et al. observed imbalances in microbial
genes involved in the degradation of
amino acids including glycine, trypto-
phan, arginine and threonine in the
metformin-untreated T2D patients (Fig-
ure 1B). Consistent with these results, a
recent study using genome-scale meta-
bolic modeling to identify the metabolic
differences between germ free and
conventionally raised mice suggested
that the gut microbiota affects theCell Metabolism 2bioavailability of free amino acids to the
host (Mardinoglu et al., 2015). Imbal-
ances in the utilization of amino acids –
particularly glycine, which is required for
the synthesis of glutathione – may affect
the biological function of the host. An
earlier study using mass spectrometry
and non-targeted biochemical profiling
showed that of all the amino acids,
plasma levels of glycine had the highest
association with increased insulin sensi-
tivity (Gall et al., 2010). Moreover, supple-
mentation with glycine has been
suggested to overcome deficiency of
glutathione synthesis and improve insulin
sensitivity in T2D patients (Sekhar et al.,
2011). Considering that glutathione is
the main detoxifying agent in the body
with a vital role in regulation of the im-
mune system, nutrient metabolism, and
other important cellular events, the gut
microbiota may therefore have direct
involvement in the occurrence of T2D
through its effect on amino acids.
The work of Forslund et al. (2015) repre-
sents a useful contribution toward our un-
derstanding of the role of the microbiome
in T2D and the response to metformin. It
suggests that future antidiabetic treat-
ment strategies could target bacterial
strains that cause imbalances in amino
acid (e.g., glycine) metabolism. These re-
sults also provide a framework for more3, January 12, 2016 ª2016 Elsevier Inc. 11
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and metabolite trafficking using genome-
scale metabolic modeling, one of the
common denominators in molecular sys-
tems biology (Shoaie et al., 2015). If the
gut microbiota is shown to promote the
onset of T2D, it may be possible to use
the gut microbiota composition to deter-
mine disease progression in individual pa-
tients. This may open up the possibility for
a precision medicine approach that com-
bines information about the patient’s gut
microbiota with other T2D risk factors,
including age, family history, and seden-
tary lifestyle.12 Cell Metabolism 23, January 12, 2016 ª20REFERENCES
Forslund, K., Hildebrand, F., Nielsen, T., Falony,
G., Le Chatelier, E., Sunagawa, S., Prifti, E.,
Vieira-Silva, S., Gudmundsdottir, V., Krogh Peder-
sen, H., et al. (2015). Nature 528, 262–266.
Gall, W.E., Beebe, K., Lawton, K.A., Adam, K.P.,
Mitchell, M.W., Nakhle, P.J., Ryals, J.A., Milburn,
M.V., Nannipieri, M., Camastra, S., et al.; RISC
Study Group (2010). PLoS ONE 5, e10883.
Karlsson, F.H., Tremaroli, V., Nookaew, I., Berg-
ström, G., Behre, C.J., Fagerberg, B., Nielsen, J.,
and Bäckhed, F. (2013). Nature 498, 99–103.
Mardinoglu, A., Shoaie, S., Bergentall, M., Ghaffari,
P., Zhang, C., Larsson, E., Bäckhed, F., and Niel-
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